News | August 08, 2025
Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Subscribe To Our Newsletter & Stay Updated
